CELLCEUTIX, Inc. (NASDAQOTH:CTIX)

CAPS Rating: 1 out of 5

Results 1 - 5 of 5

Recs

0
Member Avatar SmartAce (99.87) Submitted: 9/22/2014 3:57:41 PM : Underperform Start Price: $2.33 CTIX Score: -30.66

Yo 148, 3-to-the-3-to-the-6-to-the-9.

Recs

0
Member Avatar eyezie1 (< 20) Submitted: 4/9/2014 2:47:04 AM : Outperform Start Price: $1.57 CTIX Score: +83.82

Brilacidin is a competitor of Cubist and Durata for use in gram positive infections. FDA is fast tracking antibiotics.

Recs

0
Member Avatar adi101 (87.96) Submitted: 3/2/2014 7:45:11 AM : Outperform Start Price: $1.95 CTIX Score: +46.56

clinical stage, 3 drugs in development: new antibiotic, anti psoriasis, cancer drug.

Recs

0
Member Avatar kmac28 (< 20) Submitted: 12/9/2013 6:49:02 AM : Outperform Start Price: $1.62 CTIX Score: +75.62

Fully dependent on current FDA trials at Dana Farber Cancer institute in MA.

Recs

0
Member Avatar jed71 (65.38) Submitted: 9/12/2013 11:38:55 AM : Underperform Start Price: $1.97 CTIX Score: -35.33

Pump N Dump scam.

Results 1 - 5 of 5

Featured Broker Partners


Advertisement